PARP inhibitors in prostate cancer and the rationale behind combination treatment

In this micro learning programme, you'll learn about PARP inhibitors in prostate cancer from medical experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno. 

Learning resources include videos, slides, flashcards and assessments. Complete both modules to earn your CME credit.

What you'll learn

• Module 1 covers the use of PARP inhibitors as monotherapy in advanced prostate cancer
• Module 2 explains the rationale behind combination treatment with anti-androgens 

Clinical takeaways:

• PARP inhibitors are effective drugs as monotherapy in mCRPC patients with HRR alterations
• Genetic testing is important to help with treatment decision-making and for understanding inherited risk
• BRCA mutations are associated with poor outcomes in mCRPC patients
• Patients with tumours harbouring BRCA1/BRCA2 alterations appear to derive the greatest clinical benefit from PARPi, but patients with other HRR alterations also derive benefit
• PARP inhibitors combined with novel hormonal agents are effective as a first-line treatment option for mCRPC patients with an HRR mutation. Certain combinations, such as olaparib plus abiraterone and talazoparib plus enzalutamide, have also shown benefits in patients regardless of their HRR status